| 1 |
29643067 | Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). | 2018 Apr |
1 |
| 2 |
27868321 | Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. | 2017 Jan |
1 |
| 3 |
28720639 | Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results. | 2017 Jul-Aug |
1 |
| 4 |
27438344 | Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. | 2016 Sep 1 |
1 |
| 5 |
25677426 | Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. | 2015 Feb 24 |
1 |